O-GlcNAc engineering of GPCR peptide-agonists improves their stability and in vivo activity.
暂无分享,去创建一个
Paul M. Levine | P. Sexton | V. Katritch | T. Gardella | E. Sturchler | P. McDonald | D. Wootten | C. Koole | Matthew R. Pratt | B. Zarzycka | Tin T. Truong | M. Pratt | Aaron T. Balana | Eileen J. Daley | H. Noda | Cassandra Koole | Hiroshi Noda